Cholesterol crystal embolism, known as atheroembolic disease, is caused by showers
of cholesterol crystals from an atherosclerotic plaque that occludes small arteries. Embolization
can occur spontaneously or as an iatrogenic complication from an invasive vascular
procedure (angiography or vascular surgery) and after anticoagulant therapy. The atheroembolism
can give rise to different degrees of renal impairment. Some patients show a moderate
loss of renal function, others severe renal failure requiring dialysis. Renal outcome can be variable:
some patients deteriorate or remain on dialysis, some improve and some remain with
chronic renal impairment. Clinically, three types of atheroembolic renal disease have been described:
acute, subacute or chronic. More frequently a progressive loss of renal function occurs
over weeks. Atheroembolization can involve the skin, gastrointestinal system and central nervous
system. The diagnosis is difficult and controversial for the protean extrarenal manifestations.
In the past, the diagnosis was often made post-mortem. In the last 10 yrs, awareness of
atheroembolic renal disease has improved. The correct diagnosis requires the clinician to be
alert. The typical patient is a white male aged >60 yrs with a history of hypertension, smoking and
arterial disease. The presence of a classic triad (precipitating event, renal failure and peripheral
cholesterol crystal embolization) suggests the diagnosis. This can be confirmed by a biopsy of
the target organs. A specific treatment is lacking; however, it is an important diagnosis to make
because an aggressive therapeutic approach can be associated with a more favorable clinical
outcome. (Heart International 2006; 3-4: 155-60)
Cholesterol crystals, Renal atheroembolic disease, Atherosclerosis
Francesco Scolari, MD, Scuola di Specializzazione in Nefrologia Clinica, Università degli Studi di Brescia, UO Nefrologia, Spedali Civili, Pzle Spedali Civili 1, 25100 Brescia – Italy, fscolar@tin.it
Trending Topic
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable residual risk for cardiovascular disease (CVD) still exists despite reducing LDL cholesterol.2 Beyond traditional risk factors, other […]
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In ...
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for atherosclerotic cardiovascular disease (ASCVD). However, substantial residual cardiovascular (CV) risk remains, and there is an unmet need to reduce ...
Cardiovascular disease (CVD) represents the prevailing cause of death in the United States.1 Cancer, accidents and other prevalent causes of death, have a multitude of pathophysiologic and mechanistic underpinnings leading to mortality. Meanwhile, the majority of CVD is primarily attributable ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.